TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT06495723

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing LIS1 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

LIS1 (DRUG): The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.

Drugs / treatments
LIS1
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

NCT06495723

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is comparing LIS1 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

LIS1 (DRUG): The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.

Drugs / treatments: LIS1

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 54 patients

Primary endpoint: Dose Escalation part: Dose Limiting Toxicities (DLTs); Dose Escalation part: treatment emergent adverse events (TEAEs); Expansion part: Anti-tumors efficacy

Ages: 18 Years to —

Start date: 2024-07-09 | Est. completion: 2027-07-31

Locations

0 US sites · 8 total

Contact

Françoise SHNEIKER, MD | francoise.shneiker@xenothera.com | +33652720301

Sponsor: Xenothera SAS (INDUSTRY)

Tags

Review needed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06495723

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.